# Pregnancy of Unknown Location (PUL):

Evidence-based practices for patient-centered care

Elise Boos, MD MSc FACOG
Elise.boos@vumc.org
July 24, 2024
Destin, FL

### Disclosures

• No relevant financial relationships with ACGME defined commercial interests.

• Will discuss off-label use of mifepristone.

• Presentation adapted from presentation given with Rachel Flink-Bochacki, Misha Pangasa and Ashley Brant at Society of Family Planning Annual Meeting in Seattle in October 2024.

# Learning Objectives

- Describe diagnosis of PUL outcomes using expectant management, incorporating laboratory, ultrasound, and clinical findings.
- Describe simultaneous diagnostic and treatment strategies utilizing medication and procedural care for PUL when expectant management is not desired.
- Understand the impact of abortion climates on patient-centered care for abnormal PUL.
- Apply knowledge to PUL clinical scenario

# Background


Setting the stage

### Pregnancy of Unknown Location (PUL)

- Definition: positive pregnancy test + non-diagnostic ultrasound
- Prevalence: 8.7%
  - Recent cohort: 4.5% overall (2.5-8.4% depending on setting)



# Natural History of PUL



### PUL and ultrasound discriminatory zone


- Discriminatory zone: bHCG level where normal intrauterine pregnancy should be seen on ultrasound
  - If bHCG > DZ and no IUP is seen, assumption is that pregnancy is abnormal


#### PUL with DZ 2000-3000:


- 1.7% viable IUP
- 65.5% nonviable IUP
- 32.8% ectopic pregnancy

#### PUL with DZ > 3000:

- 0.5% viable IUP
- 66.3% nonviable IUP
- 33.2% ectopic pregnancy







### ACOG recommended DZ

- Conservatively high: 3,500 mIU/mL
- Assumes patient's values

					Highest β-hCG Where Structure
	50%	90%	95%	99%	Not Seen
Gestational sac	879 (553–1,310)	1,918 (1,368–3,970)	2,363 (1,641–5,201)	3,510 (2,294–8,910)	2,317
Yolk sac	1,826 (1,211-2,516)	5,412 (3,843-9,037)	7,832 (5,293-15,007)	17,716 (10,264-48,132)	9,975
Fetal pole	10,091 (7,753-12,619)	24,599 (20,120-31,982)	30,982 (25,021-41,374	47,685 (37,346-66,919)	35,486
* Logistic reg	ression model using fracti	in; CI, confidence interval. ional polynomials to quant ansvaginal ultrasonography.	tify the association betwe Gestational sac and fetal p	en serum β-hCG level and poole modeled using β-hCG <sup>0,5</sup> .	probability

### Management options for PUL

- Expectant management
- Active management
  - Medical
  - Surgical

### <u>Surgical management</u>

- Endometrial biopsy
- Uterine aspiration (MVA), dilation and curettage (D&C)
- Laparoscopy (with resection of ectopic)

### Medical Management

• Mifepristone + misoprostol


### Effectiveness of different treatment options

	Mifepristone + misoprostol	Misoprostol alone	Methotrexate +misoprostol	Methotrexate alone	Uterine aspiration
Undesired intrauterine pregnancy	95-99%	78-87%	89-95%	69-84%	>99% 98% if <6w
Intrauterine early pregnancy loss	80-89%	65-81%			>99%
Ectopic pregnancy				70-95%	
Pregnancy of unknown location	85%		72%	53%	

Raymond et al, Contraception (2023); Wiebe et al, Obstet Gynecol (2002); Wiebe, Contraception (1999); Barnhart et al, Fertil Steril (2004); Wiebe, Int J Gynecol Obstet (2009); Paul et al, Am J Obstet Gynecol (2002); Goldberg et al, Obstet Gynecol (2022); Ozeren et al, Contraception (1999)

# Determining success of management

- Medication management of intrauterine pregnancy
  - Mife/miso  $\rightarrow$  80% bHCG decline in 1 week
  - MTX+miso  $\rightarrow$  50% decline in 48 hours post-miso
- Medication management of ectopic pregnancy
  - MTXalone → 15% bHCG decline between day 4-7
    - Follow bHCG to negative
- Uterine aspiration
  - POC exam → chorionic villi indicate IUP
  - bHCG → >50% decrease in 12-24 hours after aspiration



# Diagnosis

Goal should be to <u>replace</u> the diagnosis of PUL with alternative diagnosis

# Expected hCG trend in normal pregnancies


- Rate of 48H rise depends on starting value.
  - Minimum expectations (1st percentile):

Initial bHCG	Minimal rate of rise in 48h
< 1,500	49%
1,500-3,000	40%
>3,000	33%

- 99% of normal intrauterine pregnancies have a rate of increase <u>faster</u> than these minimums
- hCG trend of ectopic pregnancies can mimic trend of IUP & SAB
  - Additional hCG value  $\rightarrow$  improves prediction of ultimate outcome

### Predictive tools & models

- hCG ratio
  - (48-h bHCG)/ (0-h bHCG)= bHCG ratio
    - $<0.87 \rightarrow$  Likely failed PUL
    - $\geq 0.87$  and  $\leq 1.66 \rightarrow$  Likely ectopic/PPUL
    - >1.66 → Likely ongoing IUP
- Mathematical prediction models
  - M4: bHCG ratio
  - M6: bHCG ratio + progesterone level
    - Risk stratification:
      - Risk of ectopic pregnancy
      - Risk of failed PUL
      - Chance of intrauterine pregnancy
    - External validation in US population needed



Condous et al, BJOG (2006); Barnhart et al, Hum Reprod (2010); Bobdiwala et et, Women's Health (2017); Fistouris et al, BMJ Open (2022)

### Ultrasound diagnosis

Table 2. Guidelines for Transvaginal Ultrasonographic Diagnosis of Pregnancy Failure in a Woman with an Intrauterine Pregnancy of Uncertain Viability.\*

#### **Findings Diagnostic of Pregnancy Failure**

Crown–rump length of ≥7 mm and no heartbeat

Mean sac diameter of ≥25 mm and no embryo

Absence of embryo with heartbeat ≥2 wk after a scan that showed a gestational sac without a yolk sac

Absence of embryo with heartbeat ≥11 days after a scan that showed a gestational sac with a yolk sac

#### Findings Suspicious for, but Not Diagnostic of, Pregnancy Failure†

Crown-rump length of <7 mm and no heartbeat

Mean sac diameter of 16-24 mm and no embryo

Absence of embryo with heartbeat 7–13 days after a scan that showed a gestational sac without a yolk sac


Absence of embryo with heartbeat 7–10 days after a scan that showed a gestational sac with a yolk sac


Absence of embryo ≥6 wk after last menstrual period

Empty amnion (amnion seen adjacent to yolk sac, with no visible embryo)

Enlarged yolk sac (>7 mm)

Small gestational sac in relation to the size of the embryo (<5 mm difference between mean sac diameter and crown–rump length)





<sup>\*</sup> Criteria are from the Society of Radiologists in Ultrasound Multispecialty Consensus Conference on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy, October 2012.

<sup>†</sup> When there are findings suspicious for pregnancy failure, follow-up ultrasonography at 7 to 10 days to assess the pregnancy for viability is generally appropriate.

### Prediction model incorporating US

• Sac-like structure + bHCG + absence of extraovarian adnexal mass → "virtually diagnostic of an intrauterine pregnancy"

- Pregnancy Prognosis Calculator
  - Age, MSD, bHCG and vaginal bleeding
  - Regression model AUC 0.823
  - <a href="https://tinyurl.com/Prognosis-PD">https://tinyurl.com/Prognosis-PD</a>





### Pregnancy prognos is calculator

#### **Pregnancy Prognosis**

First Trimester Prognosis Calculator For Singleton Very Early Intrauterine Pregnancy Seen on Ultrasound1

Doubilet et al\*

Double click yellow cells to enter information, then click here

Maternal age (17-45 years)	20	
Mean sac diameter (2-20 mm)	3	
Vaginal Bleeding? (Y or N)	n	
hCG rise prior to sonogram2,3	c	
A if appropriate		
S if suboptimal	3	
N if not measured		

Probability live at end of first trimester 43.9%
--

- Ultrasound demonstrates a saclike structure in the mid-uterus, without yolk sac or embryo
- 2 This calculator does not apply if serial hCG values are unchanged or decreasing
- 3 Appropriate: initial hCG <5000 that at least doubles in 2 days Suboptimal: initial hCG <5000 that fails to double in 2 days Not measured if initial hCG >5000 or serial hCG's not obtained

Based on: median change in hCG in normal pregancies is 2.24-fold rise in 2 days [Barnhart et al, Obstet Gynecol 2004;104:50-55]



What us the prognosis of a 20 y.o. with a 3 mm MSD, no vaginal bleeding and a sub-optimal rise in bHCG prior to US?



Based on anticipated MEDIAN change in bHCG → If below minimal rise expected, high likelihood for abnormal pregnancy.



Doubilet et al, JUltrasound Med (2021); Barnhart et al, Obstet Gyncol (2004)

# Patient Goals

The context to clinical decision making

# The implications of diagnostic certainty

Table 2. Guidelines for Transvaginal Ultrasonographic Diagnosis of Pregnancy Failure in a Woman with an Intrauterine
Pregnancy of Uncertain Viability.*

#### **Findings Diagnostic of Pregnancy Failure**

Crown–rump length of ≥7 mm and no heartbeat

Mean sac diameter of ≥25 mm and no embryo

Absence of embryo with heartbea ≥2 wk atter a scan that showed a gestational sacramous yolk sac

Absence of embryo with heartbeat ≥11 days after a scan that showed a gestation

#### Findings Suspicious for, but Not Diagnostic of, Pregnancy Failure†

Crown-rump length of <7 mm and no heartbeat

Mean sac diameter of 16-24 mm and no embryo

Absence of embryo with heartbeat 7–13 days after a scan that showed a gestational sac without a yolk sac

Absence of embryo with heartbeat 7–10 days after a scan that showed a gestational sac with a yolk sac

Absence of embryo ≥6 wk after last menstrual period

Empty amnion (amnion seen adjacent to yolk sac, with no visible embryo)


Enlarged yolk sac (>7 mm)

Small gestational sac in relation to the size of the embryo (<5 mm difference between mean sac diameter and crown–rump length)

Doubilet et al, N Engl J Med (2013), Judge-Golden & Flink-Bochacki, Obstet Gynecol (2021), Richardson et al, Ultrasound Obstet Gynecol (2017)

<sup>\*</sup> Criteria are from the Society of Radiologists in Ultrasound Multispecialty Consensus Conference on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy, October 2012.

<sup>†</sup> When there are findings suspicious for pregnancy failure, follow-up ultrasonography at 7 to 10 days to assess the pregnancy for viability is generally appropriate.



# Patient Attitudes and Preferences for Management of PUL

- Health of the pregnancy
- Health of self
- Future family planning
- Diagnostic certainty and prediction

Patients were constantly recalibrating their preferences in response to evolving clinical management

### **ACOG**

Consider other clinical factors when interpreting the Society of Radiologists in Ultrasound guidelines, including


- the person's desire to continue the pregnancy
- willingness to postpone intervention to achieve 100% certainty of pregnancy loss
- the potential consequences of waiting for intervention
  - the need for an unscheduled visit or procedure
- patient anxiety

It is important to include the patient in the diagnostic process and to individualize these guidelines to patient circumstances.

# Treatment Protocols

### Management of abnormal PUL

- Population: persistent PUL
- Outcome: successful resolution of pregnancy without change in management approach



### Medication abortion for PUL

• Primary outcome: time to diagnosis of pregnancy location

	Same-Day Start n=55	Delay for Diagnosis n=394	p-value
Time to diagnosis (median, days)	5	9	0.005
Ongoing Pregnancy Rate	10.4%	2.5%	0.041
Successful Medication Abortion	85.4%	96.7%	0.013
Serious Adverse Event	0	2.4%	0.611

Delay group: 18% EPL + 8% Ectopic pregnancy = 26% did not need an abortion No ectopic pregnancy in same-day MAB group

### Expected trends after treatment

- Methotrexate +/- misoprostol:
  - Expect at least 15% decline between day 4 & 7
- Uterine aspiration (12-24h post aspiration hCG)
  - <15% decline or increase = consider EP
  - >50% decline = suggest IUP
  - 49-15% decline = individualize Next page
- Mifepristone + misoprostol
  - >50% decline by 4-7 days after mifepristone (48-72h after misoprostol)
  - >80% drop in hCG by day 7 (99.5% positive predictive values for successful medication abortion)

# Following hCG after management

- Goal: Assessing need for further intervention
- Declining hCG does not negate risk of EP
  - Uterine aspiration
    - 15-49% decline @ 12-24 hours
      - 3 of 46 had persistent plateau or rising hCG necessitating treatment for EP
- ACOG: Can consider expectant management of EP only if hCG <200
- Awomen with decreasing hCG values and a possible EP should be monitored until non-pregnant values are reached.

### Post-abortion care

- Offer supportive care &use unbiased language
- Aim to understand clinical circumstances of abortion
  - No-touch vs Ultrasound?
  - Medication or procedure?
  - Were labs done?
  - Are labs needed?
- We may play a critical role in their follow-up
- Contraception

- 27 yo G3P1011 presents for OB care at 5w3d by LMP.
- Prior SVD x 1, ectopic x 1 treated with methotrexate.
- Vitals and exam WNL



- TVUS shows PUL and normal adnexa.
- bHCG: 1860 mIU/mL

Ectopic precautions Repeat hCG 48 hours


- Recommended repeat hCG @ 48h
  - $1860 \text{ mIU/mL} \rightarrow 2034 \text{ mIU/mL}$
  - 9.4% increase

- Repeat US shows only thickened EMS
- Vitals and Exam remain WNL

Initial bHCG	Minimal rate of rise in 48h
<1,500	49%
1,500-3,000	40%
>3,000	33%



- Patient discloses this is an undesired pregnancy. Her priority is preserving health and future fertility potential.
- How do you counsel this patient?



- Methotrexate + misoprostol
- Office MVA and serial hCG
- Mifepristone + miso

- Patient undergoes office MVA
  - No Villi seen
  - hCG trend
    - hCG @ MVA: 2034 mIU/mL
    - hCG @ 24 hours: 1642 mIU/mL
    - 23% decline in 24 hours = individualize
  - Patient offered continued hCG surveillance vs ectopic treatment
    - Offered surgical vs medical management, she elected for treatment with methotrexate.
    - During surveillance, she had 25% decline in hCG between D4 and D7
    - hCG trended until at non pregnant level

- Uterine aspiration (12-24h post aspiration hCG)
  - <15% decline or increase = consider EP</li>
  - >50% decline = suggest IUP
  - 49-15% decline = individualize

### Take away

- We understood patient goals
- Used a variety of modalities (hCG, US and expected clinical thresholds) to formulate plan that in our reasonable medical judgment prioritized her goals and safety.
- Expediated management = early EP diagnosis

# Questions

Elise.boos@vumc.org